HRSA Takes Step Forward on 340B Dispute Resolution Petitions

HRSA this week notified 340B covered entities that it had finished reviewing their administrative dispute resolution petitions for completeness, and determined that they were complete. | Shutterstock

The federal government on Tuesday declared 340B administrative dispute resolution (ADR) petitions by covered entities against drug manufacturers AstraZeneca, Eli Lilly, and Sanofi to be “complete,” a sign that claims against two of the three companies—AstraZeneca and Sanofi—are ready for

Read More »

Merck Pitches Its Voluntary 340B Integrity Initiative to Providers as a Better Option than Audits

Merck said in letters to 340B covered entities this week that its approach to solving problems with 340B contract pharmacy transactions "is more streamlined—and less burdensome on covered entities, HRSA, and Merck—than undertaking individual manufacturer audits" of entities and their pharmacy partners.

Drug manufacturer Merck sent letters to 340B covered entities by email on Tuesday to provide background and answer questions about its request that entities voluntarily upload their contract pharmacy claims to a vendor’s software platform so they can be checked

Read More »

Feds Oppose Hospitals’ Motion to Intervene in Novo Nordisk’s 340B Lawsuit

The federal government said this week that hospital groups should not be allowed to participate as third parties in Novo Nordisk's lawsuit against the government over enforcement of its 340B contract pharmacy requirements.

The federal government on Monday strongly objected to letting six hospital groups participate as third parties in drug manufacturer Novo Nordisk’s lawsuit challenging the government’s 340B contract pharmacy requirements.

The government’s March 22 brief in opposition the groups’ motion

Read More »

340B Gets Cameo Role in Senate Hearing on Government Drug Price Negotiation

Harvard Medical School professor Dr. Aaron Kesselheim told a Senate subcommittee yesterday, “There’s no doubt the fact that 340B pricing is among the best prices we offer for certain high-cost drugs.”

The Senate committee with direct jurisdiction over the 340B program held its first drug pricing hearing of the 117th Congress Tuesday. It held the session amid signs that House Democrats want to add language to let Medicare negotiate drug prices

Read More »

340B Dispute Resolution Injunction Is Having Ripple Effects

The federal judge considering drug manufacturer Sanofi’s motion for protection from 340B dispute resolution proceedings wants to hear more about a different court's recent decision to grant Eli Lilly such protection.

The federal judge considering drug manufacturer Sanofi’s motion for protection from 340B dispute resolution proceedings asked the company and the federal government last Wednesday to brief her on a different federal judge’s order the day before granting drug company Eli

Read More »

Federal Judge To Get Status Report Today from Ryan White Clinics and Government

HIV/AIDS clinics' and community health centers' lawsuits to force HHS to act against drug manufacturers denying 340B pricing are both being heard in federal district court in Washington, D.C.

Ryan White Clinics for 340B Access (RWC-340B) and the federal government have a deadline today to report to a federal judge about whether to continue the stay in the group’s suit to force the government to act against drug manufacturers

Read More »

Drug Pricing Is Heating Up in Congress Again

Sen. Bernie Sanders (I-Vt.) chaired today's Senate HELP subcommittee hearing on why the United States pays the highest prices in the world for prescription drugs.

A few years ago, there was hope that congressional Democrats and Republicans and the Trump administration would unite and enact legislation addressing the high price of prescription drugs.

It never happened. House Democrats passed a far-ranging drug pricing bill in

Read More »

Survey: Pharma’s 340B Contract Pharmacy Actions are Putting the Squeeze on Hospitals

Nearly all (97 percent) of all 340B hospitals in a recent survey said they are impacted by drug manufacturers' curbs on contract pharmacy use. | Shutterstock

340B hospitals are under significant pressure due to drug manufacturers ending 340B discounts on drugs dispensed by contract pharmacies, hospital advocacy group 340B Health says in its latest annual member survey.

Nearly 500 hospitals that are members of 340B

Read More »

Health Centers Get Reprieve as 340B Insulin Pricing Rule Delayed Again

HHS has for the second time delayed the effective date of a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program. The new date is July 20. | Shutterstock

The U.S. Health and Human Services Department (HHS) announced late this morning that it will delay, from this coming Monday, March 22 until July 20, the effective date of a Trump administration rule to require health centers to provide insulin

Read More »

Becerra Expected To Usher in Sea Change to 340B Governance

With Xavier Becerra in place as HHS secretary, 340B providers are hopeful he will act fast and decisively against drug manufacturers that have either stopped providing 340B discounts or placed restrictions on 340B pricing in the contract pharmacy setting. | Shutterstock

Updated, Friday, March 19, 9:30 a.m. EDT—After what initially appeared to be a rocky path to confirmation and a deadlocked vote in the U.S. Senate Finance Committee, California Attorney General Xavier Becerra (D) was confirmed today, by a 50-49 vote,

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live